Skip to search formSkip to main contentSkip to account menu

bevirimat

Known as: 3-O-(3',3'-dimethylsuccinyl) betulinic acid, 3-O-(3',3'-dimethylsuccinyl)betulinic acid 
A drug derived from a betulinic acid-like compound, first isolated from the Chinese herb Syzygium claviflorum, with activity against human… 
National Institutes of Health

Related topics

Related topics

5 relations
Bevirimat Dimeglumine

Narrower (2)

MPC-4326PA-457

Broader (2)

SuccinatesTriterpenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat
ABSTRACT Bevirimat (BVM) is the first of a new class of anti-HIV drugs with a novel mode of action known as maturation inhibitors… 
2010
2010
In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by “Deep” Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1
ABSTRACT Initial in vitro studies of bevirimat resistance failed to observe mutations in the clinically significant QVT motif in… 
2010
2010
Researchin Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat
Background: The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by… 
2010
2010
[Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
The nucleotide sequences coding the CA-SP1 Pr55(gag) in 61 samples of HIV-1 subtype A variant IDU-A isolated in Russia were… 
Review
2009
Review
2009
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has… 
2009
2009
Susceptibility of Diverse HIV-1 Patient Isolates to the Maturation Inhibitor, Bevirimat (MPC-4326*), is Determined by Clade- Specific Polymorphisms in Gag CA-SP1
16th Conference on Retroviruses And Opportunistic Infections February 8-11, 2009 Montréal, Canada Table 1: Phenotypes of clade B… 
2009
2009
High prevalence of bevirimat resistance mutations in non-B subtypes and in PI-resistant HIV isolates
2008
2008
The Maturation Inhibitor Bevirimat (PA-457) can be Active in Patients Carrying HIV type-1 non-B Subtypes and Recombinants
Background Bevirimat (PA-457) is the first candidate of a new family of antiretroviral drugs, the maturation inhibitors. Its… 
2008
2008
Formes de dosage de bevirimat liquide pour une administration orale
L'invention concerne des compositions pharmaceutiques liquides comprenant du bevirimat dimeglumine en tant que substance… 
2008
2008
Bevirimat beneficial for treatment-experienced patients with HIV
  • 2008
  • Corpus ID: 195111888
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)